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Introduction
The World Health Organization
(WHO) has been criticized recently for
not consistently making recommendations
based on systematic reviews of the best
available evidence and for the quality of
some of its guidelines [1–3]. In 2007,
WHO put in place procedures for devel-
oping transparent, evidence-based guide-
lines based on the Grading of Recom-
mendations Assessment, Development and
Evaluation (GRADE) methodology [4,5].
This methodology, developed by an inter-
national network of methodologists with
an interest in grading quality of evidence
and strength of recommendations (Box 1),
has now been used to produce WHO
guidelines for several topics. These include
rapid advice guidelines for the pharmaco-
logical management of human H5N1 virus
infection [6,7] and guidelines on a single
specific clinical topic such as psychosocial-
ly assisted pharmacological treatment of
opioid dependence [8]. However, the
GRADE approach has not yet been
applied to develop recommendations that
cover a broad range of conditions and
interventions.
WHO is in the process of developing a
model intervention guide within its mental
health Gap Action Programme (mhGAP)
[9]. The model intervention guide pro-
vides recommendations to facilitate care at
first and second level facilities by the non-
specialist health care providers in low- and
middle-income countries (Box 2). These
recommendations will be based on the
GRADE approach. To our knowledge,
this is the first exercise involving a
systematic evaluation of evidence in this
area. Other initiatives, for example the
recently published reviews of evidence for
packages of care for mental, neurological,
and substance use disorders in low- and
middle-income countries, did not use
GRADE methodology [10]. This paper
describes the use and adaptation of the
GRADE approach in developing the
guidelines for the mhGAP model inter-
vention guide.
Overview of the Process
The pathway describing the process of
recommendation development is present-
ed in Figure 1. A network of experts were
identified to convene the Guideline De-
velopment Group (GDG), taking into
consideration multidisciplinary expertise
and adequate regional and gender repre-
sentation. The multidisciplinary expertise
included guideline development method-
ology, mental health, neurology, substance
use, primary care, public health, epidemi-
ology, and policy making. A review of
potential conflicts of interest was carried
out in agreement with the WHO hand-
book [5]. The GDG developed scoping
questions and defined outcomes. For each
scoping question, evidence was aggregated
and synthesized following the GRADE
methodology. The evidence profiles were
then supplemented by noting values,
preferences, and feasibility considerations.
Recommendations were subsequently
drafted and submitted to the GDG for
review, modification, and approval.
We report here some challenges en-
countered during the process of evidence
review and developing recommendations.
Developing recommendations in the con-
text of these disorders is complex, as
evidence directly from low- and middle-
income settings is still limited, and values,
preferences, and feasibility issues tend to
play a large role in informing recommen-
dations.
Challenges: From Scoping
Questions to Evidence Profiles
Formulating Questions and Rating
Outcomes
The pathway from defining scoping
questions to developing evidence profiles
is described in Figure 2. Scoping questions
were formulated using the PICO frame-
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ator, Outcome) [11], which was useful for
translating narrative questions into a
format suitable for searching and synthe-
sizing evidence. The conditions considered
of high priority for low- and middle-
income countries reported in Box 2 were
the focus of scoping questions. In addition
to scoping questions, outcomes critical or
important for evidence review and deci-
sion making and recommendations were
agreed upon by the GDG. A key challenge
was that there was an enormous number
of potential questions, which would re-
quire years to answer. Thus, when formu-
lating and selecting scoping questions,
GDG members were asked to identify
the most important questions, including
any areas of uncertainty or controversy or
where changes in policy or practice was
needed. For example, given that in some
countries the proportion of individuals
with epilepsy who do not receive adequate
drug treatment is high, with controversy
related to side effects of anti-epileptic
drugs, one scoping question focused on
the beneficial and harmful consequences
of these drugs. We note that getting the
scoping right is critical to the overall
process of making recommendations.
Identification of critical and important
outcomes was a crucial process, as out-
comes guided the subsequent phases of
evidence retrieval, synthesis, and making
recommendations. Based on the GRADE
methodology, outcomes were grouped into
three categories: critical, important, and
not important. Very often, clinical trials
report those outcomes (e.g., symptoms)
that can be easily measured, while omit-
ting other key outcomes (e.g., human
rights violations) that are more difficult to
quantify. During the outcome rating
process, the GDG members explicitly
considered the value of choosing and
rating outcomes that should be measured
rather than those that have been mea-
sured.
Selecting the Measure That Best
Describes Each Outcome
For each scoping question, the experts
and WHO focal points formed review
teams that as a first step searched for
systematic reviews from databases and
existing evidence-based guidelines that
have tried to answer a similar scoping
question. In case no synthesized evidence
was available, new systematic reviews were
commissioned. The review teams summa-
rized the evidence base using the GRADE
profiler software, a tool developed to help
transparently summarize the evidence and
grade its quality (see Box 1). The GRADE
process required us to summarize evidence
and grade its quality for each of the
outcomes, using systematic reviews and
meta-analyses. It often happened that, for
each outcome, more than one measure
was available in the selected systematic
review. This introduced potential incon-
sistency and bias because no explicit
criteria were available to guide the selec-
tion of the measure for one outcome. This
issue is especially challenging in the field of
mental health, as outcomes are typically
measured by means of rating scales, and
very often several rating scales purporting
to measure the same concept are included
in trials and meta-analyses. Systematic
reviews may consequently include four to
five measures for the same outcome.
In our process, to increase transparency
and consistency between raters, explicit
instructions were developed to help re-
viewers use the same background logic in
making the choice (Text S1), although the
possibility of adopting a different logic was
considered acceptable if justified and
reported. We note that the absence of
instructions on using GRADE leaves the
possibility of inconsistency and bias, be-
Box 1. Main Features of the GRADE Methodology
GRADE is an approach for creating clinical practice guidelines based on an explicit
assessment of the evidence base.
GRADE is not a system for performing systematic reviews and meta-analyses (it is
not a systematic review tool as, for example, the RevMan software of the
Cochrane Collaboration at http://www.cc-ims.net/revman).
The GRADE approach is suitable for (a) summarizing the evidence extracted from
systematic reviews and meta-analyses into ‘‘Summary of Findings (SoF) tables’’;
(b) grading the quality of evidence summarized in SoF tables; and (c) grading the
strength of treatment recommendations.
GRADE separates the judgment on quality of evidence from strength of
recommendations.
An application called GRADE Profiler (GRADEpro) has been developed to
summarize the evidence and grade its quality. GRADEpro can be freely
downloaded at http://www.gradeworkinggroup.org/toolbox/index.htm.
Additional information on the GRADE methodology and on the GRADE working
group can be found at http://www.gradeworkinggroup.org/index.htm.
Box 2. Rationale for Developing WHO Recommendations for
Mental, Neurological, and Substance Use Disorders
Mental, neurological, and substance use (MNS) disorders are prevalent
throughout the world and are major contributors to morbidity and premature
mortality. The treatment gap for these disorders is more than 75% in many low-
and lower-middle income countries. Substantial initiatives have been made by in
the last decade to bring mental health onto public health agenda [24–26],
however the task is far from complete. To address this challenge, WHO launched
the mental health Gap Action Programme (mhGAP) to scale up mental health
services, especially in low- and middle-income countries (LAMIC) [9]. An essential
component of mhGAP is to develop a model intervention guide for MNS
disorders identified as conditions of high priority for LAMIC. The priority
conditions were identified on the basis of high mortality and morbidity, high
economic costs, or association with violation of human rights within the area of
MNS disorders. These are depression, schizophrenia and other psychotic disorders
(including bipolar disorder), suicide prevention, epilepsy, dementia, disorders due
to use of alcohol and illicit drugs, and mental disorders in children.
Recommendations (i.e., guidelines) on interventions for the management of
such high priority conditions form the basis of the mhGAP model intervention
guide. Interventions are targeted to health care providers working at a first and
second level facility in a health center at a peripheral level or at district level. The
first and second level facility includes the basic outpatient and inpatient services
provided at these levels. The health care providers could be doctors, nurses, or
other cadre of health workers.
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choose the measures with the results that
better match their a priori opinions.
Reproducibility and Consistency
One of the key challenges in evaluating
the quality of evidence with GRADE is
that some factors (i.e., limitations and
indirectness) imply a judgement on the
quality of a group of trials, while other
factors (i.e., inconsistency, imprecision,
publication bias) imply a judgement on
the meta-analytic process of data aggre-
gation (see Box 3 for a definition of these
terms). This implies that reviewers, either
implicitly or explicitly, are asked to make
a different reasoning according to the
dimension that is considered: for the
factor limitation, for example, raters need
to judge the risk of bias of each single
trial included in the selected systematic
review and, secondly, to make a judg-
ment on whether the estimated propor-
tion of trials at risk of bias causes a risk of
bias for the entire evidence base. In areas
where there are only a few trials this may
not be a serious challenge. In areas
characterized by the presence of many
randomized trials, however, such as
antidepressants for major depression
w h e r es i n g l er e v i e w sm a yi n c l u d em o r e
than 100 trials, this posed a practical
problem, in terms of feasibility (to access
all primary studies), and also in terms of
reproducibility and consistency [12]. For
dimensions that refer to the meta-analytic
process, only a single judgment is re-
quired, but even in this case it is very
likely that different raters would apply
different criteria, and that the same rater
m a yi m p l i c i t l ya p p l yd i f f e r e n tc r i t e r i ai n
different situations.
Problems with reliability in GRADE are
particularly problematic when several
raters are involved in the development of
recommendations, which is often the case
for development of guidelines covering a
broad range of conditions. We therefore
reasoned that raters should follow the
same background logic in assessing the
evidence and developed pragmatic in-
structions to guide the process of grading
the quality of the evidence (Text S1), to
increase the reproducibility of the process
and the consistency of judgements. If the
instructions were not followed in any
specific circumstances, raters were re-
quired to record a reason.
We note that our instructions are
inevitably based on rules of thumb in
many cases, and may not be automatically
extrapolated from one guideline to anoth-
er, because criteria are based on the
perspective that the guideline developers
assume and are tuned to the relevant
clinical area.
Publication Bias
According to the GRADE methodolo-
gy, raters should assess the possibility of
publication bias. We note that the instru-
ments for making such a judgment are
inadequate. We tried to rely on the funnel
plot, although its use is controversial
[13,14] and often was not reported in
systematic reviews. We thus used the
additional pragmatic criterion of checking
if the authors of the systematic review
Figure 1. Pathway describing the process of recommendation development. The Guideline Development Group (GDG) developed the
scoping documents and the scoping questions. For each scoping question, a WHO working group drafted evidence profiles and profiles
incorporating values, preferences, and feasibility considerations. Recommendations were subsequently drafted and submitted to the GDG for review
and approval.
doi:10.1371/journal.pmed.1000322.g001
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tried to make an additional judgment on
whether outcome reporting bias might
have occurred. Also, in the latter case,
instrumentation was a problem: study
protocols were generally not available,
and the feasibility of checking this aspect
in hundreds of clinical trial is very low.
Although publication bias is probably one
of the most relevant aspects of the whole
process of summarizing and grading the
quality of evidence, we realize that only
weak methods are currently available to
detect it.
Evidence from Non-Randomized
Trials
For many clinical questions, more often
than not, evidence in the form of random-
ized trials is not available. Epidemiological
studies and qualitative studies cannot
easily be described in GRADE tables,
and a risk exists of omitting the contribu-
tion of non-randomized research in the
development of the evidence profiles. For
example, the value of asking about suicide
ideation of individuals with specific mental
disorders has never been investigated
through clinical trials, but still there is
indirect epidemiological evidence suggest-
ing that asking increases detection with no
major drawbacks, and increased detection
is associated with increased treatment and
better outcomes. Although this issue was
addressed by requiring the inclusion of
additional evidence in a narrative section
of the evidence profiles, this remains a
weak aspect of the whole process. Even for
observational studies that investigate the
beneficial or harmful effects of interven-
tions, grading is rarely straightforward, as
systematic reviews of these studies are
typically not available, and the meta-
Figure 2. From scoping questions to evidence profiles: flow-chart describing the process to identify, summarize, and rate the
evidence for each scoping question.
doi:10.1371/journal.pmed.1000322.g002
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may often be methodologically inappro-
priate.
We note that the systematic omission of
some non-randomized evidence from
GRADE inevitably creates an imbalance
between low- and high-level quality of
evidence, with low value and consider-
ation given to what is kept out from
GRADE tables. This may represent a
serious bias in the process of guideline
development, considering that each re-
search question requires a proper research
design, and clinical trials cannot provide
an answer to all health-related questions
[15].
Challenges: From Evidence to
Recommendations
Scientific Evidence versus Values,
Preferences, and Feasibility Issues
The pathway from aggregating and
grading the quality of evidence to devel-
oping recommendations is described in
Figure 3. While the methodology for
developing guidelines is highly developed
for aspects related to summarizing and
judging the evidence base [16–19], the
methodology for taking into consideration
aspects related to values, preferences, and
feasibility issues is much less developed.
We have sought to address this imbalance
by developing a checklist (Box 4) and a
template (Figure 3) that give equal
relevance and visibility to both aspects,
i.e., the evidence base and the value/
preferences and feasibility issues. Firstly,
for each scoping question, the review
teams summarized the evidence included
in the GRADE tables and its quality
ratings, and drafted a narrative descrip-
tion of the balance between desiderable
and undesiderable effects. This formed
the basis for the ‘‘zero draft recommen-
dation’’. Secondly, the review teams were
required to take into consideration values,
preferences, and feasibility issues. A
checklist of aspects that deserve consider-
ation was developed to increase consis-
tency across scoping questions (Box 4). A
modified recommendation, based on the
evidence base and on the considerations
on values, preferences, and feasibility
issues, was then drafted and reported in
the table.
This approach allows for the transpar-
ent reporting of how recommendations
derived from the scientific evidence may
then be modified due to the weight given
to other factors (Figure 3). For example,
medication treatments backed by robust
evidence, such as lithium in the treatment
of mood disorders, may not be recom-
mended if regular blood checks, and their
interpretation, are not feasible, or if
regular drug supply cannot be assured.
Similarly, psychological interventions,
such as full cognitive behavioral therapy,
may not be feasible in many low- and
middle-income settings considering the
training, supervision, and time needed
for this intervention, and that they might
need local adaptations to context and
culture.
Recommendations When There Is
No or Poor Quality Evidence
For certain key areas, the conventional
way of evaluating the quality of evidence
revealed no or very poor quality evidence
that was not sufficient to make any
recommendation. In such instances we
relied on the consensus of GDG consist-
ing of international experts, who applied
their professional experience and their
tacit knowledge. Value-based decisions
in mental health are unavoidable, as
violation of human rights of people with
mental disorders is common. For exam-
ple, for the strategies aimed at improving
community attitudes towards people with
mental, neurological, and substance use
conditions, the evidence base is very poor
and indirect. Nevertheless, because of
strong values and the importance of
improving community attitudes, the
GDG made a recommendation to con-
sider planning and implementation of
activities such as anti-stigma campaigns.
We note that the added value of GRADE
in these circumstances is that it is
required to transparently report that
some recommendations are based on
strong values and weak evidence. The
GDG was also requested to make specific
statements for recommending research in
a r e a sw h e r et h e r ei sap a u c i t yo fe v i d e n c e
(Figure 3).
Applicability
While themainfocus of WHO’s mental
health work was to develop recommen-
dations for health care providers in low-
and middle-income settings, most of the
evidence comes from specialist settings of
high-income countries. We tried to ad-
d r e s st h i sc o n c e r na sf o l l o w s .F i r s t ,t h e
GRADE assessment of directness was
used to downgrade the quality of evidence
if there were concerns about generalisa-
bility of population, intervention compar-
a t o r ,o ro u t c o m e .A d d i t i o n a l l y ,w ei n -
cluded a judgment on the extent to which
the characteristics of those who would
deliver the intervention in the real world
(including context characteristics) match
with the characteristics of those who
actually delivered the intervention under
experimental conditions (e.g., in terms of
background education, training, referral
possibilities, context). A further aspect
was the availability of implementation
studies conducted in low- and middle-
income countries. For example, the
applicability of some brief psychological
treatments in low-income settings has
been documented in research projects
carried out in Uganda and Pakistan [20–
22], and the results of these practical
experiences have been given value in
judging the applicability of the interven-
tion and in drafting the recommenda-
tions. We realize that despite the fact that
these strategies helped mitigate this issue,
increasing research in the contexts where
the guidelines should eventually be ap-
plied is essential to enhance the applica-
bility of research findings into practice.
Box 3. Factors to Consider in the Assessment of the Quality of
the Evidence according to the GRADE Approach
Study limitations: Limitations in the study design that may bias the overall
estimates of the treatment effect.
Inconsistency: Unexplained differing estimates of the treatment effect (i.e.,
heterogeneity or variability in results) across studies.
Indirectness: The question being addressed by the guideline panel is different
from the available evidence regarding the population, intervention, comparator,
or outcome.
Imprecision: Results are imprecise when studies include relatively few patients
and few events and thus have wide confidence intervals around the estimate of
the effect.
Publication bias: Systematic underestimate or overestimate of the underlying
beneficial or harmful effect due to the selective publication (or reporting) of
studies.
PLoS Medicine | www.plosmedicine.org 5 August 2010 | Volume 7 | Issue 8 | e1000322Figure 3. From evidence profiles to recommendations: template describing how evidence, values, preferences, and feasibility
issues were considered in making recommendations.
doi:10.1371/journal.pmed.1000322.g003
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Our experience suggests that GRADE
may be applied as a useful technical
framework for synthesizing and presenting
evidence on the effectiveness of clinical
interventions. It is a helpful tool to uncover
implicit subjectivity, since it requires a
systematic, explicit, and judicious ap-
proach to interpreting evidence [23].
However, the process may be further
improved in the following domains: inclu-
sion of non-randomized evidence and
evidence that cannot be meta-summarized
and analyzed; better reproducibility and
internal consistency; and consideration of
the choice of one among several measures
for each outcome to reduce the selection
bias. Development of recommendations is
a complex process that not only involves
systematic review and assessment of qual-
ity of evidence and balance of benefits and
harms, but also explicit consideration of
other issues such as value judgments,
resource use, and feasibility, which are
major considerations. The technicality of
GRADE needs to be supplemented by a
careful analysis of these additional but
essential issues.
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